CN102432549A - 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法 - Google Patents
一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法 Download PDFInfo
- Publication number
- CN102432549A CN102432549A CN201110294713XA CN201110294713A CN102432549A CN 102432549 A CN102432549 A CN 102432549A CN 201110294713X A CN201110294713X A CN 201110294713XA CN 201110294713 A CN201110294713 A CN 201110294713A CN 102432549 A CN102432549 A CN 102432549A
- Authority
- CN
- China
- Prior art keywords
- acid
- preparation
- barbituric acid
- dicyclohexyl
- dicyclohexyl barbituric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- SPGPSFWOMJQSDF-UHFFFAOYSA-N ethyl 4-oxo-6-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound C1=C(C(F)(F)F)C=C2C(=O)C(C(=O)OCC)=CNC2=C1 SPGPSFWOMJQSDF-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title abstract description 4
- 201000010099 disease Diseases 0.000 title abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 3
- 230000002062 proliferating effect Effects 0.000 title abstract description 3
- 208000005623 Carcinogenesis Diseases 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 230000036952 cancer formation Effects 0.000 title abstract 2
- 231100000504 carcinogenesis Toxicity 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 230000004862 vasculogenesis Effects 0.000 claims description 12
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 claims description 10
- 206010020718 hyperplasia Diseases 0.000 claims description 8
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000012450 pharmaceutical intermediate Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 2
- -1 propionic anhydride class acid anhydrides Chemical class 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 abstract 2
- 239000012024 dehydrating agents Substances 0.000 abstract 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 8
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 2
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical class CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 1
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110294713.XA CN102432549B (zh) | 2011-09-28 | 2011-09-28 | 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110294713.XA CN102432549B (zh) | 2011-09-28 | 2011-09-28 | 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102432549A true CN102432549A (zh) | 2012-05-02 |
CN102432549B CN102432549B (zh) | 2014-09-03 |
Family
ID=45980942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110294713.XA Expired - Fee Related CN102432549B (zh) | 2011-09-28 | 2011-09-28 | 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102432549B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151254A (zh) * | 2014-07-25 | 2014-11-19 | 南通市华峰化工有限责任公司 | 一种制备1,3-双环己基巴比妥酸的方法 |
CN105801490A (zh) * | 2016-05-05 | 2016-07-27 | 青岛辰达生物科技有限公司 | 一种制备阿格列汀中间体的方法 |
IT202100020591A1 (it) * | 2021-07-30 | 2023-01-30 | Dipharma Francis Srl | Preparazione di un intermedio di un agente per il trattamento dell'anemia |
WO2024022998A1 (en) | 2022-07-26 | 2024-02-01 | Inke, S.A. | Process for preparing daprodustat and cocrystals thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022263899A1 (en) * | 2021-06-18 | 2022-12-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel manufacturing method of daprodustat and precursors thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002265456A (ja) * | 2001-03-13 | 2002-09-18 | Fuji Photo Film Co Ltd | バルビツール酸誘導体の製造方法 |
US7074925B1 (en) * | 1998-05-26 | 2006-07-11 | Rimma Lliinichna Ashkinazi | N-substituted derivatives of 5-oxyiminobarbituric acid |
CN101190898A (zh) * | 2006-11-30 | 2008-06-04 | 上海三爱思试剂有限公司 | 一种1,3-二甲基巴比妥酸的制备方法 |
CN101505752A (zh) * | 2006-06-23 | 2009-08-12 | 史密丝克莱恩比彻姆公司 | 脯氨酸羟化酶抑制剂 |
-
2011
- 2011-09-28 CN CN201110294713.XA patent/CN102432549B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074925B1 (en) * | 1998-05-26 | 2006-07-11 | Rimma Lliinichna Ashkinazi | N-substituted derivatives of 5-oxyiminobarbituric acid |
JP2002265456A (ja) * | 2001-03-13 | 2002-09-18 | Fuji Photo Film Co Ltd | バルビツール酸誘導体の製造方法 |
CN101505752A (zh) * | 2006-06-23 | 2009-08-12 | 史密丝克莱恩比彻姆公司 | 脯氨酸羟化酶抑制剂 |
CN101190898A (zh) * | 2006-11-30 | 2008-06-04 | 上海三爱思试剂有限公司 | 一种1,3-二甲基巴比妥酸的制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151254A (zh) * | 2014-07-25 | 2014-11-19 | 南通市华峰化工有限责任公司 | 一种制备1,3-双环己基巴比妥酸的方法 |
CN105801490A (zh) * | 2016-05-05 | 2016-07-27 | 青岛辰达生物科技有限公司 | 一种制备阿格列汀中间体的方法 |
IT202100020591A1 (it) * | 2021-07-30 | 2023-01-30 | Dipharma Francis Srl | Preparazione di un intermedio di un agente per il trattamento dell'anemia |
WO2024022998A1 (en) | 2022-07-26 | 2024-02-01 | Inke, S.A. | Process for preparing daprodustat and cocrystals thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102432549B (zh) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102432549B (zh) | 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法 | |
CN105254603B (zh) | 呋喃铵盐的合成工艺 | |
CN104610250A (zh) | 含三个氮杂环的1,2,3-噻二唑-5-甲脒类化合物及合成 | |
WO2020107515A1 (zh) | 一种制备3-羟基丁酸盐的方法 | |
CN104262285B (zh) | 农用杀虫剂茚虫威中间体的合成法 | |
CN102503825A (zh) | 药物中间体丁酮二酸二酯类化合物的制备方法 | |
CN105218445B (zh) | 一种酪氨酸激酶抑制剂Foretinib的制备方法 | |
CN103724203B (zh) | 邻羟基苯乙酸甲酯的制备方法 | |
CN107903209A (zh) | 一种2‑氨基‑5‑氟吡啶‑3‑甲酸甲酯的合成方法 | |
JP2008260725A (ja) | 2−イミノ−4−チアゾリジノンの製造方法 | |
CN105130962A (zh) | 一种四嗪吡唑类杀螨剂 | |
CN105037059A (zh) | 一种α-(4-取代苯基)异丁酸的制备方法 | |
CN102180844A (zh) | 吉非替尼中间体及吉非替尼的制备方法 | |
CN102146075B (zh) | 一种喹唑啉化合物的制备方法 | |
Rao et al. | Protection-free, short, and stereoselective synthesis of ieodomycin A and B | |
CN104356076A (zh) | 一种取代2,3-二氢-4(1h)-喹唑啉酮类化合物的合成方法 | |
CN105566231A (zh) | 一种基于Suzuki反应制备嘧菌酯的方法 | |
CN107915715A (zh) | 一种瑞舒伐他汀钙侧链关键中间体的合成方法 | |
CN103965104B (zh) | 一种酪氨酸激酶抑制剂及其中间体的制备方法 | |
CN105061430A (zh) | 一种抗肿瘤化合物的制备方法和用途 | |
CN101434533B (zh) | 一种新型的索法酮制备方法 | |
CN103570649A (zh) | 一种5-羟基-4-甲基-2(5h)-呋喃酮的合成方法 | |
CN101891737A (zh) | 一种Lewis酸催化氨解合成美洛昔康的方法 | |
CN108727187A (zh) | 一种(r)-(+)-2-对羟基苯氧基丙酸的制备方法 | |
CN105367483A (zh) | 盐酸多奈哌齐的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Defeng Inventor after: Shi Langyin Inventor after: Zhang Yaobing Inventor after: Zhang Yancheng Inventor before: Wang Defeng Inventor before: Wang Bingcai Inventor before: Zhu Haifeng Inventor before: Zhu Xiaofei Inventor before: Yu Jianjun |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG DEFENG WANG BINGCAI ZHU HAIFENG ZHU XIAOFEI YU JIANJUN TO: WANG DEFENG SHI LANGYIN ZHANG YAOBING ZHANG YANCHENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161019 Address after: 226500 Zhang Yang village, Shi Zhuang Town, Jiangsu, Rugao Patentee after: Hung Nantong f.d.l. Chemical Co. Ltd. Address before: The Yangtze River town of Rugao city of Jiangsu province in 226500 in Nantong city (Rugao port) Yuejiang Road No. 28 Patentee before: Huafeng Chemical Co., Ltd., Nantong City |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161229 Address after: 226500 Zhang Yang village, Shi Zhuang Town, Jiangsu, Rugao Patentee after: Huafeng Chemical Co., Ltd., Nantong Address before: 226500 Zhang Yang village, Shi Zhuang Town, Jiangsu, Rugao Patentee before: Hung Nantong f.d.l. Chemical Co. Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171215 Address after: 065402 Langfang city of Hebei province Xianghe County ZTE Backstreet No. 11 Tin Yuet District Building 3 room 2201 unit 2 Patentee after: Jiang Shulin Address before: 226500 Zhang Yang village, Shi Zhuang Town, Jiangsu, Rugao Patentee before: Huafeng Chemical Co., Ltd., Nantong City |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140903 Termination date: 20190928 |